PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1
文献类型：期刊论文
| 作者 | Xie, Fei1; Zhang, Han1; Zhu, Kongkai2; Jiang, Cheng-Shi3; Zhang, Xiaoya4; Chang, Hongkai1; Qiao, Yaya1; Sun, Mingming1; Wang, Jiyan1; Wang, Mukuo1 |
| 刊名 | MedComm
 |
| 出版日期 | 2023-04-01 |
| 卷号 | 4期号:2页码:e245 |
| ISSN号 | 2688-2663 |
| DOI | 10.1002/mco2.245 |
| 文献子类 | Article |
| 英文摘要 | MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.Protein arginine methyltransferase 5 (PRMT5) is a major type II enzyme responsible for symmetric dimethylation of arginine (SDMA), and plays predominantly roles in human cancers, including in ovarian cancer. However, the exactly roles and underlying mechanisms of PRMT5 contributing to the progression of ovarian cancer mediated by reprogramming cell metabolism remain largely elusive. Here, we report that PRMT5 is highly expressed and correlates with poor survival in ovarian cancer. Knockdown or pharmaceutical inhibition of PRMT5 is sufficient to decrease glycolysis flux, attenuate tumor growth, and enhance the antitumor effect of Taxol. Mechanistically, we find that PRMT5 symmetrically dimethylates alpha-enolase (ENO1) at arginine 9 to promotes active ENO1 dimer formation, which increases glycolysis flux and accelerates tumor growth. Moreover, PRMT5 signals high glucose to increase the methylation modification of ENO1. Together, our data reveal a novel role of PRMT5 in promoting ovarian cancer growth by controlling glycolysis flux mediated by methylating ENO1, and highlights that PRMT5 may represent a promising therapeutic target for treating ovarian cancer. |
| WOS关键词 | alpha‐enolase (ENO1) ; glycolysis flux ; ovarian cancer ; protein arginine methyltransferase 5 (PRMT5) ; symmetric dimethylation of arginine (SDMA) |
| 语种 | 英语 |
| WOS记录号 | MEDLINE: 36999124 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/309617]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Zhao, Jianguo; Luo, Cheng; Zhang, Shuai; Shan, Changliang |
| 作者单位 | 1.State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research Nankai University Tianjin China. 2.Advanced Medical Research Institute Shandong University Jinan China. 3.School of Biological Science and Technology University of Jinan Jinan China. 4.Biomedical Translational Research Institute Jinan University Guangzhou Guangdong China. 5.School of Integrative Medicine Tianjin University of Traditional Chinese Medicine Tianjin China. 6.Tianjin Key Laboratory of human development and reproductive regulation Tianjin Central Hospital of Obstetrics and Gynecology Tianjin China. 7.Research Center The Fourth Hospital of Hebei Medical University Shijiazhuang Hebei China. 8.The Sixth Affiliated Hospital of Guangzhou Medical University Qingyuan Guangdong China. 9.Department of Colorectal Surgery, Tianjin Union Medical Center Nankai University Tianjin China. 10.Department of Pathology, Medical School Dalian University Dalian Liaoning China. |
| 推荐引用方式 GB/T 7714 | Xie, Fei,Zhang, Han,Zhu, Kongkai,et al. PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1[J]. MedComm,2023,4(2):e245. |
| APA | Xie, Fei.,Zhang, Han.,Zhu, Kongkai.,Jiang, Cheng-Shi.,Zhang, Xiaoya.,...&Shan, Changliang.(2023).PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1.MedComm,4(2),e245. |
| MLA | Xie, Fei,et al."PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1".MedComm 4.2(2023):e245. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。